Kintara Therapeutics received a letter from Nasdaq stating that they are not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
AI Assistant
TUHURA BIOSCIENCES INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.